Guangzhou, China, October 19, 2026 /PRNewswire/ – POMDOCTOR LIMITED (hereinafter referred to as “Pomdoctor” or “the Company”) ( NASDAQ : POM ) is a digital healthcare company dedicated to advancing artificial intelligence ( AI ) enabled healthcare solutions. The Company announced today that it has initiated the termination of its American Depository Receipts program (“ADR Program”), including the termination of the revised related deposit agreements, and will list the Company’s Class A common shares directly on the NASDAQ Stock Market Limited Liability Company (“NASDAQ”).

The company stated that the aforementioned termination was previously approved by the Pomdoctor Board of Directors on September 3, 2026, and was also approved by the company's shareholders in a non-binding consultative manner at the special general meeting of shareholders held on September 30, 2026.

The ADR plan proposed to be terminated this time was established in accordance with the 'Depository Agreement' dated October 9, 2025, as amended. This agreement was jointly signed by the company, Citibank ( Citibank , N.A , namely the 'Depositary'), as well as the holders and beneficial owners of the American depositary receipts ( ADS ) issued thereunder.

ADR and the Depositary Agreement are expected to terminate before the opening of trading on October 21, 2026. At that time, in accordance with the Depositary Agreement, the company's ADS will be compulsorily cancelled and exchanged for Class A ordinary shares allocated to the holders of ADS ("compulsory exchange").

The company stated that, with the termination of the ADR plan taking effect, the company will implement a share consolidation for Class A common shares and Class B common shares. Accordingly, every ten (10) shares of each category of common shares will be consolidated into one (1) share of the same category of common shares ("share consolidation"). Due to this share consolidation and mandatory exchange, each holder of ten (10) ADS shares will receive three (3) shares of the consolidated Class A common shares.

Related to the termination of the ADR plan and share consolidation, the company plans to list its Class A common stocks on NASDAQ to replace ADS. The company expects that its Class A common stocks will begin trading on NASDAQ on October 21, 2026, with the trading code remaining “POM”, and the new CUSIP number will be G7166T112.

The company has designated TranShare Corporation as its transfer agent for Class A common shares in the United States.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED ( NASDAQ : POM ) is a digital healthcare company dedicated to advancing AI enabled healthcare solutions and expanding predictive healthcare capabilities. The company leverages physician resources, wearable technology, artificial intelligence, healthcare payment networks, and real-world medical data to support more personalized, continuous, and data-driven healthcare services. Building on its existing healthcare platform and physician network, POM is working to establish infrastructure for predictive healthcare data and services, with the aim of improving healthcare outcomes and creating long-term value for patients, healthcare providers, and other stakeholders in the ecosystem. For more information, please visit the company's website: http :// ir.7shiliu.com.

Forward-looking Statements

This announcement contains forward-looking statements as defined by Section 27A of the Securities Act of 1933 (as amended), Section 21E of the Securities Exchange Act of 1934 (as amended), and the Private Securities Litigation Reform Act of 1995. Such statements are made under the ‘Safe Harbor’ provisions of the Private Securities Litigation Reform Act of 1995. Except for historical facts, all statements are forward-looking and include, but are not limited to: the company’s strategy to drive the transformation of healthcare from a passive response model to a predictive and proactive model; the company’s plans to integrate AI, wearable technology, remote patient monitoring (RPM) capabilities, and real-world medical data with existing healthcare operations and physician resources into a coordinated healthcare management framework; the company’s efforts to build infrastructure for predictive medical data and services; the company’s belief that its existing healthcare infrastructure and technical capabilities provide a foundation for a more continuous, data-driven, and proactive healthcare model; expectations regarding the future role of predictive healthcare, including its role in chronic disease management; and the expected benefits that the company’s strategy will bring to patients, healthcare providers, and other stakeholders in the ecosystem, including improved healthcare outcomes and the creation of long-term value.

Investors may identify many (but not all) of these forward-looking statements through the use of terms such as “approximates”, “believes”, “hopes”, “expects”, “anticipates”, “aims”, “estimates”, “projects”, “intends”, “plans”, “pursues”, “positions”, “will”, “would”, “should”, “could”, “may”, etc. These forward-looking statements are based on the company's current expectations, assumptions, and forecasts regarding future events, which the company believes may affect its financial condition, operating results, business strategy, and financing needs. They involve known and unknown risks and uncertainties, many of which are beyond the company's control. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee that these expectations will ultimately prove to be correct, and investors should not rely excessively on them. All forward-looking statements are as of the date of this announcement. Except as required by law, the company assumes no obligation to publicly update or revise any forward-looking statements.

The company stated that due to various factors and uncertainties, the actual results may differ significantly from those indicated or implied in these forward-looking statements. The company urges investors to refer to the 20-F annual report submitted to the U.S. Securities and Exchange Commission (SEC) on May 14, 2026, for the fiscal year ending December 31, 2025, specifically the "Item 3 Key Information—D. Risk Factors" section, as well as other documents submitted by the company to SEC. Relevant documents can be found on the SEC website at www.sec.gov.

For more information, please contact:

POMDOCTOR LIMITED

Ascent Investor Relations LLC